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ABSTRACT
Goeckerman therapy is a highly effective treat-
ment regimen for moderate-to-severe psoriasis.
It involves regular exposure to ultraviolet B radia-
tion and the application of crude coal tar. To our
knowledge, only three centers in theUSA currently
offer a formal Goeckerman therapy treatment pro-
gram; thus, access to this therapy is geographically
limited. In this article, amotivatedpatientdiscusses
his experience with generalized plaque psoriasis.
This patient, while living in a Goeckerman-inac-
cessible area, deferred treatment with biologics and
outpatient phototherapy to develop a modified
Goeckerman regimen for at-home use. This home
regimen, which did not involve the use of pre-
scription-strength medications, resulted in full
clearance of his psoriasis. We also discuss the
patient’s case fromtheperspectiveofadermatology
treatment team that has reviewed his experience.
Keywords: Coal tar; Goeckerman therapy;
Heliotherapy psoriasis; Home therapy;
Phototherapy
Key Summary Points
Gockerman therapy is a well-established
and efficacious treatment for plaque
psoriasis that involves the use of topical
crude coal tar (CCT) and phototherapy
with ultraviolet B light.
Many patients are unable to receive office-
based Gockerman therapy due to
geographic limitations.
This patient-provider perspective article
demonstrates how one patient was able to
use over-the-counter CCT products and
heliotherapy to treat his plaque psoriasis
with a home-based, modified Goeckerman
regimen under the supervision of his
dermatologist.
Home-based therapies for plaque psoriasis
that are modified from evidence-based
techniques may be safely adapted for
patients who are otherwise unable to
receive treatment.
Collaboration between physicians and
patients is crucial for developing new,
creative treatment regimens.
The article is part of the Topical Collection on Patient.
Enhanced Digital Features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.11898216.
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PATIENT’S EXPERIENCE
My psoriasis first introduced itself as a peculiar,
dry patch on my left shin. It seemed innocuous
at first. I dismissed it, hoping the dry skin would
resolve on its own. But after a couple weeks, it
started to itch almost every night, flaking off a
thin layer of dead skin when scratched. This was
odd and disconcerting. I decided to take more
decisive action. I doused it with layers of various
topical creams: lotion, cocoa butter, and petro-
leum jelly. But the dry patch endured.
And then—to my horror—multiplied.
Over 7 months, from October 2017 to May
2018, reddish coin-shaped patches peppered my
shin and calves on my left leg, then on my right
leg. The patches then crawled up, popping up
on my inner thighs, chest, and elbows. I had
hoped the warmer months would help alleviate
my condition. But on the first week of May, yet
another red patch appeared. This time on my
nose, like a big teenage pimple on my 34-year-
old face.
I made an appointment with a local derma-
tologist. He took a punch biopsy from my left
leg, and the results led to the conclusion that I
had plaque psoriasis, an incurable autoimmune
disease. Psoriasis was not directly life-threaten-
ing, as far as incurable diseases go. I tried to
remind myself that I got the luckier end of the
deal, but ‘‘incurable’’ is such a hope-snuffing
word. A slight melancholy usually descended
after a shower—when my red plaques were at
their brightest. I attentively examined the pla-
que on my face, looking for any sign of
improvement. Any fleeting thought of chang-
ing my circumstances was immediately reined
in by the weight of the word ‘‘incurable.’’
Living with psoriasis is an exercise in expert
cover-ups. Pants and long sleeve shirts—even in
the summer—were my staple outfit, and my
uniform for recreational flag football tourna-
ments now included knee-high socks. The
raised, reddish plaques itched intensely, often at
night. And every couple of days, a thin layer of
skin would rapidly build up on my plaques and
then slough off and crumble, leaving trails of
skin flakes behind on my clothes and bedsheets.
At my next appointment, the dermatologist
prescribed clobetasol 0.05%, a potent topical
corticosteroid cream. I applied it on my plaques
twice daily for 2 weeks, but my plaques
remained fairly unchanged. I understood that
should the corticosteroids fail, the dermatolo-
gist would next consider a biologic treatment,
such as Humira (adalimumab) or Taltz (ixek-
izumab). I was generally wary of this option for
a number of reasons: life-long dependence,
potential immunosuppressant side effects, and
an expensive price tag. For me, this seemed like
a last resort option; I wanted to first exhaust
other reasonable alternatives.
I was fairly open to telling my friends and
family about my diagnosis and, in doing so,
received two unexpected benefits. First, they
shared with me their experiences with psoria-
sis—either those of their own or those of a
family member who had the disease. Before I
received the diagnosis, I did not think I per-
sonally knew anyone who had psoriasis; I was
surprised to learn how far from alone I actually
was. Second, they shared stories of different
remedies that they had tried, including what
seemed to help and what didn’t. For 8 months,
my psoriasis showed no signs of abatement.
Their stories restored some hope that perhaps a
treatment could at least reduce the number of
my plaques.
Through personal conversations and reading
online articles, I compiled a list of potential
psoriasis treatments: a vegan diet, gluten-free
diet, keto diet, a vegan and keto diet, alkaline
water, potent ingestible probiotics, cold show-
ers, a probiotic skin spray, all sorts of different
moisturizers, and an Ayurvedic solution from
India. I downloaded an app called Imagine that
helped to organize time-lapsed photos of dif-
ferent parts of the body. Through the app, I
could take daily pictures of one body part, such
as my left leg, and then easily swipe through the
time-stamped photos to determine whether
there were any noticeable changes in the
appearance of the plaques. Using my body as a
live science experiment, I introduced and tested
each potential psoriasis treatment and docu-
mented the results. After force-drinking daily
cups of concentrated probiotic solutions, tem-
porarily dying my skin red from the Ayurvedic
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solution, nearly starving myself for 2 weeks on a
keto-vegan diet that consisted mostly of
pumpkin seeds, and gathering my nerves before
every ice-cold shower, my psoriasis plaques—
showing complete disdain for my efforts—re-
mained unchanged. The cycle continued with-
out disruption: flare up, skin buildup, itch all
over, shedding of a skin layer, and repeat. Dis-
heartened, I had to admit that my ‘‘throw the
kitchen sink’’ strategy had failed.
I was disappointed yet still felt duty-bound
to continue. I took a sober, realistic attitude
toward my psoriasis, under no illusion that the
chances of finding a non-prescriptive remedy to
reduce the severity of my disease was anywhere
within the realm of possibility. But I was fueled
by the simple thrill of the challenge and the
obligation to try.
I decided to take a more thoughtful
approach: to replace my Google searches with
Google Scholar searches to delve down into the
peer-reviewed medical literature and to better
understand the pathology of the disease. When
interesting online publications were blocked by
pricey paywalls, I leaned on the kindness of
physician and pharmacist friends at academic
hospitals and asked whether they could send
me the full-length articles. I read through study
after study, cataloging the conclusions of vari-
ous experiments as far back as the 1920s,
drawing out the pathways of cytokine overex-
pression and forming hypotheses on the nature
of the disease.
In late July 2018, I read an article published
in 2013 by the University of California, San
Francisco (UCSF) that had caught my eye,
entitled The Goeckerman Regimen for the Treat-
ment of Moderate to Severe Psoriasis. UCSF has one
of three clinics in the USA that administers the
Goeckerman regimen, and the reported statis-
tics from this clinic were incredible. According
to this article, ‘‘100% of patients on Goecker-
man therapy achieved PASI 75 [75% improve-
ment of Psoriasis Assessment of Severity Index
(PASI) from baseline] by 3 months.’’ I thought:
100% of patients responded to the treatment? After
all my experimentation, I had not witnessed a
glimmer of a response. And here, at this clinic,
every patient did. The article continued: ‘‘…pa-
tients on the most potent biologics achieved
only 67–68% PASI 75 in 3 months.’’ The
Goeckerman regimen was not only more effec-
tive than the leading biologic (as of 2013), but it
even worked on patients who did not respond
to biologic treatment. To top it off, the regimen
had ‘‘an extremely safe toxicity profile with
essentially no internal side effects.’’ The article
detailed a 24-step process on how to perform
the Goeckerman regimen, which consisted of
ten topical applications and phototherapy
treatments. One Goeckerman session requires
approximately 6 h to complete. The session is
performed daily on the patient until the symp-
toms clear. The total treatment period can range
anywhere between 3 and 8 weeks.
Despite the extraordinary promise of the
therapy, there were several logistical and
financial challenges: Should I take potentially
8 weeks off of work to pursue this? How expensive
would it be to travel to San Francisco and find
temporary housing? Would my health insurance
cover the UCSF Goeckerman therapy? If not, how
much would it cost out of pocket? As the questions
piled up, a seditious thought arose. A thought
that would render the current questions moot,
but would open a new phase of my own
research and experimentation: If this therapy is
remarkably safe, how hard would it be to replicate it
at home?
The bulk of Goeckerman studies were con-
ducted in the 1970s and 1980s. From what I
gathered, it might be possible to boil down the
24-step UCSF Goeckerman regimen to three
essential elements: a topical coal tar applica-
tion, plastic wrap occlusion, and exposure to
narrowband ultraviolet B (UVB) light. Although
coal tar and UVB light can independently help
alleviate some psoriatic symptoms, there was a
powerful synergistic therapeutic effect when
used together. I set out to acquire each of the
essential ingredients required to replicate a
similar effect at home.
I bought a small jar of coal tar online and a
roll of plastic wrap from my local grocery store.
But the challenge was finding a narrowband
UVB light source as home phototherapy units
were exorbitantly expensive and often required
a prescription. After brainstorming alternative
options, I arrived at this—it turns out, incor-
rect—conclusion: If the Goeckerman therapy was
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invented in the 1920s, Dr. Goeckerman probably
didn’t use a phototherapy unit. He must have used
the sun (Dr. Goeckerman had actually used
medium pressure mercury arc lamps). I neglec-
ted to do a simple Google search to confirm my
assumption and just—well—ran with it.
After an inquiry into UV radiation, I learned
that the amount of UVB light from the sun that
reaches the earth’s surface is dependent on
multiple factors, including geographical loca-
tion (e.g., latitude), time of the year, time of the
day, altitude, weather, air pollution, etc. At the
time, I was traveling for work to the suburbs of
Baltimore in late July. Based on my rough esti-
mates, in order to harness the most heliothera-
peutic radiation for Goeckerman, I needed to
expose large swaths of my skin to the sun
sometime between the hours of 11 a.m. and
2 p.m. This inconveniently was smackdab in the
middle of the workday. To properly test this
improvised Goeckerman therapy, two words
came to mind: ‘‘strategic lunchbreaks.’’
The coal tar had the color of brown mustard
and a semi-solid consistency similar to petro-
leum jelly. At my hotel in Baltimore, I used
latex gloves to rub a thin layer of the ointment
onto my psoriasis plaques. I held one end of the
plastic wrap in place with one hand, and then
with the other I slowly unspooled the plastic
wrap from the roll, circling and occluding most
of my affected skin. Once the wrapping process
was complete, I ripped the plastic wrap free
from the roll and tucked the end under another
plastic wrap swatch, securing it in place with a
piece of tape. I slept overnight with the plastic
occlusions wrapped around my legs and arms. I
reasoned that this activity fulfilled the 4? h
plastic wrap occlusion wait time—a critical step
in the UCSF Goeckerman regimen. The follow-
ing morning, I unwrapped the plastic wrap and
thoroughly washed off the coal tar from my
skin with soap and water. The ointment had a
faint smell of tar, but it was barely perceptible
on my skin after the shower.
The next critical step was the UVB radiation
exposure. I left work around noon for ‘‘lunch’’
and drove back to the hotel, which was luckily
only a quick 5-min drive away. In my hotel
room, I stripped down and changed into just a
pair of shorts and flip flops, and with a couple
towels draped over my shoulder, I headed back
outside. As I passed the front desk, I heard a
voice, ‘‘Sir, are you looking for the swimming
pool?’’
‘‘No, no. Just the parking lot,’’ I replied, giv-
ing a slight jerk of my head toward the main
entrance.
‘‘Oh…okay.’’
After an awkward pause, I gently nodded and
walked through the sliding double doors.
A small field hugged the far end of the
parking lot and a lone wooden picnic bench sat
along the field’s edge. I placed a large towel flat
on top of the table and laid down on top of it,
facing the sky. It was a clear day, and the
unobstructed sun lit up my saddle-colored skin
to a shade of chestnut, bespeckled with crimson
red spots. I wore sunglasses to protect my eyes,
but for additional protection, I folded a small
hand towel and placed it over my face as well.
I knew that exposing large areas of bare
unprotected skin to the noonday sun was
against commonly held wisdom. There was
even a warning label on my jar of coal tar that
advised to ‘‘use caution in exposing skin to
sunlight’’ after using the product. To mitigate
the risk of sunburn, I used an equation that
considered the daily UV index and my Fitz-
patrick skin type to estimate the time it would
take my skin to burn. To play it even safer, I
arbitrarily multiplied that estimate by 10%,
which often came out to approximately 10 min.
I lay out baking in the sun with my cell-
phone timer set for 10 min. My eyes closed, I
could feel a blanket of warm radiation gently
press down on my body.
My timer went off. I reset it for another
10 min and flipped over, face down. After the
timer went off a second time, I gathered my
towels and headed back to the hotel. I rinsed off
my skin in the shower, changed back into my
button-down collared shirt and trousers, and
drove back to work. That evening, I checked my
skin. Luckily, there were no tell-tale signs of
sunburn.
As often as the weather and my work
schedule permitted, I repeated this procedure:
apply coal tar and occlude skin in the evening;
expose skin to UVB light at noon; and periodi-
cally evaluate for any sunburn or adverse
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reactions. After the first week, I noticed some-
thing remarkable. The psoriasis plaques had
visibly flattened and turned a lighter shade of
red with splotches of darkened skin. Something
was happening—finally!
In mid-August, about 3 weeks into the
improvised Goeckerman treatment, I made an
appointment at my local dermatologist office. I
wanted to get advice from a professional on
whether my skin’s unusual response to the
treatment was an indication that the psoriasis
plaques were healing. ‘‘No,’’ the dermatology
physician assistant said. ‘‘It hasn’t healed. The
way you can tell is if you close your eyes, run
your fingers along the skin, and see whether you
can feel a difference between the plaques and
your normal skin.’’
‘‘I see,’’ I said, as I followed her instruction,
‘‘you can still feel some raised plaques, but it
does look a lot different than it did just a few
weeks ago.’’
I told her the story of my improvised
Goeckerman treatment, but she remained
skeptical. ‘‘I would recommend you try one of
the biologics.’’
I squinted an eye into a slight grimace. ‘‘I
want to see how this goes first before going
down that route,’’ I replied. ‘‘Can I ask though—
it seems you’re skeptical of this type of pho-
totherapy—why?’’
‘‘It’s just I’ve seen patients do phototherapy
at the office and it works for a while but then it
often comes back. With a biologic, you don’t
have to see me again for another 6 months.’’
She gave me a prescription for another type
of topical corticosteroid and said I could try to
continue to do what I was doing if it seemed to
be helping.
I never filled the prescription. After 3 more
weeks on the home Goeckerman therapy, my
psoriasis plaques were gone. There was no trace
of my plaques on my arms and chest and
thighs; it looked like normal skin. The plaques
on my shin and calves were also gone, but had
left behind darkened, hyperpigmented skin in
their absence. The psoriasis plaque on my nose
had healed as well. This was a fascinating detail:
I did not want to experiment with my face so I
never applied coal tar on my nose and covered
up my face, nose included, with a towel when
exposing my body to UVB light. Despite this,
this plaque too disappeared.
To put it mildly, I was very satisfied with the
results. But the words of the dermatology
physician assistant stayed with me, ‘‘…it often
comes back.’’ For good measure, I continued the
home Goeckerman therapy for another 4 weeks
(Fig. 1).
Throughout the winter in Chicago, there was
no trace of the plaques returning. When spring
arrived, I took up the habit of a weekly 4-mile
run at noon along the lake with my shirt off—
my bare, exposed skin absorbing the heliother-
apeutic UVB light. When the psoriasis plaques
hadn’t returned in about 1 year, I decided it was
time to share my experience and further explore
the feasibility of this therapy option for others.
I started by extending my gratitude to the
physicians, researchers, and medical students
who authored the publication on the UCSF
Goeckerman regimen. The UCSF paper was
instrumental in developing the home version of
the therapy that ultimately healed my plaques.
Dr. Wilson Liao, co-author of this article,
replied to my thank you email and inquired for
more details on my experience. We discussed
the risks and promises of adapting the Goeck-
erman regimen for home use, and he encour-
aged me to share my story through a medical
journal publication.
With only a sample size of one, I wanted
more assurance that what worked for me could
be safely and reliably repeated for other psoria-
sis patients. I shared a post on my Instagram
with before and after pictures of my psoriasis,
encouraging readers to contact me if they, or
someone they knew, had psoriasis. Over dozens
of calls and coffee chats, I heard stories of how
my friends, former colleagues, and acquain-
tances had suffered from psoriasis, including
the physical and emotion toll it caused over the
years, how they thought through the available
treatment options, and how they currently
manage the disease. I shared my experience and
the treatment I had used to send my psoriasis
into full remission. If they were willing to try
the home Goeckerman regimen, I asked if they
could check in with me weekly so I could track
their progress and results.
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Some who only had a mild form of psoriasis
were less willing to put in the effort that the
home Goeckerman treatment required. For the
ones that attempted the treatment, the critical
step to absorb UVB light was often obstructed
by their work schedules or uncooperative
weather. But for the ones that consistently
adhered to the treatment, the results were
impressive. One man in his mid-30 s had pso-
riasis for 4 years. He had been on Humira, a
biologic, which helped to reduce most of his
psoriasis plaques, but he still had plaques on his
shins. He tried the home Goeckerman ther-
apy—while continuing his Humira treatment—
and after just 4 weeks, the psoriasis plaques on
his shins showed what he estimated as 80%
improvement.
MEDICAL PROVIDER PERSPECTIVE
Mr. Thomas first reached out to the clinical
research team at the UCSF Psoriasis and Skin
Treatment Center after performing his own
personal research on the Goeckerman regimen.
We thought it was fascinating that Mr. Thomas
took the initiative to modify the Goeckerman
regimen for home use, based on his personal
situation and treatment preferences. For inter-
ested readers, we have provided a description of
his protocol (Table 1), the over-the-counter
materials used (Table 2), and the method of
calculating UV light dosage from sun exposure
(Table 3). Mr. Thomas has agreed to voluntarily
share his experience on his own accord in order
to potentially help other patients who may
benefit from his approach.
Goeckerman therapy, originally developed
in 1925 at the Mayo Clinic, has proven to be
highly effective for the treatment of moderate-
to-severe psoriasis [1]. Although the mechanism
of coal tar has not been definitively identified,
some evidence suggests that polycyclic aryl
hydrocarbons may be responsible for the
majority of its therapeutic effect in psoriasis
[2, 3]. Goeckerman therapy has been used suc-
cessfully in cases of treatment-resistant psoriasis
and in patients who have contraindications to
biologic medications [4, 5]. While useful for
patients in these scenarios, Goeckerman ther-
apy has traditionally been administered as an
inpatient or formal outpatient treatment pro-
gram, requiring patients to either live nearby or
travel regularly to a treatment center. We were
intrigued by Mr. Thomas’ case as many patients
who reach out to our center and are interested
in pursuing Goeckerman therapy report an
inability to do so because of geographic and
scheduling limitations.
Despite these limitations, Goeckerman ther-
apy remains one of the most effective treat-
ments for plaque psoriasis. One study of UCSF
Fig. 1 Progression of plaque psoriasis treatment on left leg
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Table 1 Our patient’s approach to the Goeckerman regimen for home use
Evaluation and
preparation
A. Confirmed with licensed dermatologist that he was an appropriate candidate for Goeckerman
regimen. Patient qualified because he did not have a known history of adverse reactions to
ambient sunlight or light therapy and was not taking any photosensitizing medications
B. Purchased the necessary materials (Table 2)
Application of coal
tar
A. Applied generous amounts of coal tar gel to areas where psoriasis was present
B. Occluded coal tar gel with plastic wrap. (For hand psoriasis, gloves are typically used for
occlusion. For scalp psoriasis, a shower cap is used. For foot psoriasis, a shower cap placed inside a
sock is used)
C. Maintained occlusion for at least 4 h. Performed application and occlusion prior to sleeping and
wore occlusive materials overnight
D. After a minimum of 4 h, removed occlusive materials and washed off tar in the shower with soap
and water. Applied mineral oil on occasion to help remove coal tar
E. Used a variety of moisturizers as needed (Aquaphor, VanicreamTM, and Cetaphil) following
coal tar removal to prevent irritation and dryness
Heliotherapy A. For heliotherapy, patient used the Environmental Protection Agency UVI to calculate the UVI
based on zip code. He then used a formula (Table 3) based on Fitzpatrick skin type to calculate
time-to-burn for his skin. Once time-to-burn was calculated, he arbitrarily began heliotherapy at
15% of time to burn. For example, for the first session, if the patient’s calculated time-to-burn
was 100 min, he would spend 15 min exposed to the sun while lying supine and 15 min exposed
while lying prone. The patient wore shorts and covered his face, but exposed all other areas of his
body given that psoriasis was present in multiple locations
B. Monitored for over-exposure to UVB radiation. Although the patient never experienced
significant erythema, irritation, or burning, he planned to either reduce or stop exposure to UV
radiation if these side effects occurred. Patient also followed-up with dermatologist following
initiation of home Goeckerman therapy once during treatment and once after treatment
following symptom resolution
UVB Ultraviolet B, UVI ultraviolet index
Table 2 Modified home Goeckerman therapy materials
Purpose Material(s)
Crude coal tar (CCT) MG217 psoriasis 2% coal tar multi-symptom ointment
MG217 psoriasis medicated conditioning 3% coal tar formula shampoo
Occlusion Plastic wrap
Shower cap (scalp psoriasis)
Plastic gloves (hand psoriasis)
Disposable socks/booties (foot psoriasis)
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Goeckerman patients found that 100% of
patients achieved 75% improvement in the
Psoriasis Area and Severity Index score (PASI 75)
following treatment [6]. Another study exam-
ining 300 patients in both Baylor University
and UCSF’s Goeckerman centers found that
100% of psoriasis patients achieved 90%
improvement in the PASI score (PASI 90), with
73% of patients remaining in remission for at
least 12 months [7]. Goeckerman therapy,
however, has steadily lost favor due to the time
commitment required from patients, typically
4–6 h/day for 6 weeks in a clinical setting. This
is one of the main reasons why only a handful
of clinics in the USA currently offer Goecker-
man therapy. Mr. Thomas’ case demonstrates
that an excellent skin response is possible when
utilizing a modified at-home Goeckerman regi-
men. This regimen also provides an opportunity
to significantly increase the availability of
Goeckerman therapy to patients who are unable
to pursue formal therapy due to geographic,
financial, or time constraints. Additionally,
office-based Goeckerman therapy has also been
used in other dermatologic conditions apart
from psoriasis, including atopic dermatitis and
prurigo nodularis [8, 9]. The modified home
Goeckerman therapy presented here may also
prove to be successful in treating these other
dermatologic conditions.
There are, however, potential risks to this
approach that should be discussed. In formal
Goeckerman therapy programs, patients are
examined daily by a dermatologist to evaluate
treatment progression and monitor for burns
secondary to phototherapy. This allows for
subsequent titration of phototherapy dosage if
necessary. An at-home regimen inherently
involves less monitoring and may result in
unintentional injury, although Mr. Thomas did
not experience any adverse events. Dermatolo-
gists should educate patients on the photosen-
sitizing potential of crude coal tar (CCT) and on
how to monitor for signs of burning and sting-
ing, particularly for patients with Fitzpatrick
skin types I–IV. Furthermore, it is also impor-
tant to educate patients on normal skin changes
throughout this process, including the post-in-
flammatory hyperpigmentation seen in Mr.
Thomas’ case and the potential need for main-
tenance therapy to prevent remission. It is also
crucial to maintain open communication
throughout the process if patients wish to ini-
tiate heliotherapy while using concomitant
CCT. Adverse reactions to ultraviolet A in sun-
light may not manifest until 48 h following
exposure [10]. One option to minimize this risk
would be to utilize a home phototherapy unit
prescribed by a dermatologist. Another poten-
tial concern relates to the use of topical corti-
costeroids in conjunction with CCT, which is
often done at formal Goeckerman therapy cen-
ters under the supervision of a clinician.
Although Mr. Thomas did not utilize topical
corticosteroids for his treatment, there is a the-
oretical risk of excessive systemic absorption if
patients apply and then occlude topical corti-
costeroids on a large body surface area for
extended periods of time. To mitigate any
medical–legal liability, providers can ask
patients to sign an educational form confirming
that the patient understands the risks and
Table 3 Heliotherapy calculation used by patient
Skin type Unexposed skin color Reaction to sun exposure Time to burn (min)
I White Always burns, never tans (200 9 2.5)/(3 9 UVI)
II White Always burns, minimal tan (200 9 3)/(3 9 UVI)
III White to olive Burns minimally, gradually tans (200 9 4)/(3 9 UVI)
IV Light brown Burns minimally, tans well (200 9 5)/(3 9 UVI)
V Brown Very rarely burns, tans profusely (200 9 8)/(3 9 UVI)
VI Dark brown to black Never burns, tans deeply (200 9 15)/(3 9 UVI)
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benefits of an at-home regimen, which has not
been studied in a large cohort of patients. This is
an approach used by physicians who prescribe
home phototherapy. Additional studies are
necessary to determine if home Goeckerman
therapy is as effective and safe as its traditional
counterpart.
Patient-centered treatment options are cru-
cial for increasing access to medical treatment.
The availability of at-home care for conditions
such as psoriasis is an important goal. Home
phototherapy units, for example, have proven
to be successful despite initial concerns about
safety and efficacy [11]. Additionally, preserving
patient autonomy is fundamental to providing
medical care within the context of a shared
decision-making model. As such, physicians
must not shy away from beneficial patient-di-
rected treatments, particularly in cases in which
patients are willing to adhere to at-home treat-
ment and when at-home treatment can facili-
tate therapies that would otherwise be
unavailable to patients or too burdensome to
pursue. For patients to make informed deci-
sions, all clinicians should provide the most up-
to-date and comprehensive information avail-
able regarding diagnoses and efficacy and safety
profiles of all available therapeutic options.
Patients who have interest and are motivated,
such as Mr. Thomas, should also be included in
the early stages of developing research propos-
als (i.e., clinical trials), systematic reviews, and
clinical practice guidelines. Finally, as in Mr.
Thomas’ case, patient-directed treatments can
also promote dialogue and community devel-
opment between patients who share similar
experiences and may benefit significantly from
peer support. This article is based on previously
conducted studies and does not contain any
studies with human participants or animals
performed by any of the authors.
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